rAAV8 Vector for Sustained Anti-VEGF Expression in Retina
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for wet age-related macular degeneration (AMD) require frequent intravitreal injections of VEGF inhibitors, which are inconvenient for patients and pose additional risks, as they provide limited and temporary relief, with recurring neovascularization remaining a challenge.
Innovation Solution
A recombinant adeno-associated virus (rAAV) vector with an AAV8 capsid is used for sub-retinal and/or intra-retinal injection, carrying a vector genome that produces a soluble antigen-binding fragment of a human monoclonal antibody against vascular endothelial growth factor (VEGF), offering continuous delivery and reducing the need for repeated injections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If frequent intravitreal injections of VEGF inhibitors are administered, then neovascularization is inhibited and disease progression is slowed, but patient convenience deteriorates and cumulative injection risks increase
Solution Approach 1:
The patent applies preliminary action by using rAAV vectors to deliver genetic material that encodes anti-VEGF antibodies, establishing continuous therapeutic production within the eye before neovascularization recurs. This upfront genetic intervention creates sustained VEGF inhibition without requiring repeated injections, resolving the contradiction between maintaining disease control and preserving patient convenience
Solution Approach 2:
The patent implements self-service through self-sustaining transgene expression systems where the rAAV-delivered genetic constructs continuously produce anti-VEGF antibodies within ocular tissues. The system serves itself by maintaining therapeutic antibody production autonomously over time, eliminating the need for repeated external injections while sustaining disease control
2Reliability
If frequent intravitreal injections of VEGF inhibitors are administered, then neovascularization is inhibited, but cumulative injection risks increase
Solution Approach 1:
The patent applies preliminary action by establishing continuous anti-VEGF antibody production through rAAV-mediated gene delivery before neovascularization can recur. This single upfront intervention creates sustained therapeutic effect, eliminating the need for repeated injections and their associated cumulative risks while maintaining reliable neovascularization inhibition
Solution Approach 2:
The patent implements self-service through autonomous transgene expression within ocular tissues that continuously produces anti-VEGF antibodies. This self-sustaining system maintains therapeutic antibody levels without external intervention, thereby preventing neovascularization recurrence while avoiding the cumulative injection risks that would otherwise accumulate
3Ease of operation
If single administration of rAAV8.aVEGF is used, then injection frequency is reduced and convenience is improved, but sustained therapeutic effect must be achieved
Solution Approach 1:
The patent applies continuity of useful action through sustained transgene expression from the rAAV-delivered genetic constructs. The continuous production of anti-VEGF antibodies within ocular tissues maintains therapeutic effect over extended periods, achieving both reduced injection frequency and prolonged duration of action simultaneously
Solution Approach 2:
The patent implements self-service through self-sustaining genetic expression systems that autonomously produce therapeutic anti-VEGF antibodies within the eye. This single administration establishes a self-renewing therapeutic source that maintains effective antibody levels over time, resolving the contradiction between minimizing injection frequency and ensuring sustained therapeutic effect
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The rAAV8 vector achieves continuous expression of anti-VEGF throughout the retina, potentially improving therapeutic outcomes by providing sustained VEGF inhibition and minimizing the frequency and risks associated with repeated ocular injections.
Implementation Method 1
The AAV8 capsid packages a vector genome that provides for the production of a soluble antigen-binding fragment (Fab) of a human monoclonal antibody (MAb) that binds and inhibits human vascular endothelial growth factor (hVEGF)
Data Source
AI summary
A recombinant adeno-associated virus (rAAV) having an AAV8 capsid which is suitable for intra-retinal injection is provided herein. The rAAV comprises a vector genome packaged within the capsid which contains, operably linked to regulatory elements which direct expression of anti-human vascular endothelial growth factor (VEGF) antigen binding antibody fragment (aVEGF), a coding sequence for aVEGF, wherein the coding sequence is operably linked to regulatory elements which direct expression of the anti-VEGF Fab in the eye. Also provided herein are liquid suspensions containing these rAAV8.aVEGF and methods of using same for treatment of wet AMD and other ocular conditions.